HOECHST-ROUSSEL's MERITAL APPROVAL WAS BASED ON THREE PIVOTAL STUDIES OUT OF 17, FDA's TEMPLE TESTIFIES ON HILL; REP. WEISS ASKS FDA TO REVIEW FIRM's REPORTING